Navigation Links
Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
Date:1/5/2011

WAYLAND, Mass., Jan. 5, 2011 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing an innovative platform technology to deliver orally-active antibodies to the gastrointestinal tract, announced today that it has generated compelling pre-clinical data in animal models of inflammatory bowel disease (IBD). Avaxia's orally administered anti-TNF product AVX-470 significantly reduced disease severity in three different animal models and showed superior efficacy to an oral steroid drug in a comparative test of disease remission. Dr. Barbara Fox, founder and Chief Executive Officer, will present these data at the Biotech Showcase 2011, being held on January 10-12, 2011 in San Francisco, California.

Dr. Fox's presentation will take place at 3:15 PM on Wednesday January 12 at the Parc 55 Wyndham San Francisco Hotel. The presentation will include positive efficacy data from three animal models of IBD, including statistically significant efficacy in a remission model of the disease.  Dr. Fox's presentation will also include efficacy data from an experiment that compared AVX-470 to an oral steroid in a DSS-induced colitis model of IBD.  Dr. Fox commented that, "We believe these consistent and statistically significant results in the standard animal models of IBD indicate that our orally administered anti-TNF product has the potential to become a leading therapy for inflammatory bowel disease, a chronic and debilitating disease of over a million and a half North Americans and four million people worldwide.  We are also heartened to observe that our product has shown superior efficacy to an oral steroid drug in a comparative test of disease remission.  With these impressive results, and with the support of our scientific advisors, Avaxia plans to enter into clinical trials with AVX-470 in patients with IBD this year.  AVX-470 appears to be on track to be the first orally-active anti-TNF antibody for IBD."

About Inflammatory Bowel Diseases: Inflammatory bowel diseases incur significant personal and societal costs. For example, the primary symptoms of both Crohn's disease and ulcerative colitis are abdominal pain, diarrhea and bleeding. These diseases typically present at a young age, and most patients require lifelong therapy. Chronic drug therapy, hospitalization, and surgery are common and are associated with significant morbidity. Approximately 1 million people in the U.S. suffer from these diseases, with the prevalence equally divided between Crohn's disease and ulcerative colitis. A study carried out in the early 1990s estimated the direct and indirect economic burden of $1.8 - $2.6 billion per year.

About Avaxia Biologics, Inc.:  Avaxia Biologics (www.avaxiabiologics.com) is an early stage company developing orally-delivered antibody therapeutics. The antibodies are designed to treat both diseases of the GI tract and systemic diseases where the disease targets are accessible in the GI tract. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, oral mucositis, celiac disease, and diabetes and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/5/2017)... 5, 2017  Xyntek Inc. has announced another milestone in their continued growth ... to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite ... Xyntek's ... ...
(Date:9/1/2017)... , Sept. 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ... greatest aural experiences — and deliver these experiences as part ... help people feel and heal better. ... While nothing beats a walk, jog ... your mind, Life Environments™ is the next best thing when ...
Breaking Medicine Technology:
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... to help you brush more effectively even on the go. Their electric toothbrushes ... gingivitis and gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology ...
(Date:9/22/2017)... ... September 22, 2017 , ... Global Lyme Alliance ... research, education and awareness, today announced the appointment of Timothy J. Sellati, Ph.D. ... Sellati has more than 20 years of research experience with Lyme and other ...
(Date:9/21/2017)... ... 21, 2017 , ... The American Addiction Treatment Association (AATA) ... in the addiction treatment industry entitled: Special Investigations Unit (SIU) – What ... state and federal governments are increasingly scrutinizing the addiction treatment industry for fraudulent ...
(Date:9/21/2017)... ... , ... In addition to sticking with the new years ... and use natural alternatives for all house cleaning products, disinfectants, respiratory relief, and ... the new line of essential oils, are all 100% organic and natural. , ...
(Date:9/21/2017)... RICHMOND, Va. (PRWEB) , ... September 21, 2017 ... ... Richmond with a different approach to addiction recovery at a time when Virginia ... 1,420 deaths resulting from drug overdose, a staggering increase of 38 percent from ...
Breaking Medicine News(10 mins):